In Vitro Evaluation of Antimicrobial Activity of Lactic Acid Bacteria against Clostridium difficile.
- Author:
Joong Su LEE
1
;
Myung Jun CHUNG
;
Jae Gu SEO
Author Information
1. R&D Center, CellBiotech, Co. Ltd., Gyunggi, Korea. jgseo@cellbiotech.com
- Publication Type:In Vitro ; Original Article
- Keywords:
Clostridium difficile infection;
lactic acid bacteria;
antimicrobial activity;
cell-free supernatant
- MeSH:
Bacteria;
Bifidobacterium;
Clostridium;
Clostridium difficile;
Coculture Techniques;
Complementary Therapies;
Lactic Acid;
Lactobacillus rhamnosus;
Probiotics;
Public Health;
Pyridines;
Sprains and Strains;
Thiazoles
- From:Toxicological Research
2013;29(2):99-106
- CountryRepublic of Korea
- Language:English
-
Abstract:
Clostridium difficile infection (CDI) has become a significant threat to public health. Although broad-spectrum antibiotic therapy is the primary treatment option for CDI, its use has evident limitations. Probiotics have been proved to be effective in the treatment of CDI and are a promising therapeutic option for CDI. In this study, 4 strains of lactic acid bacteria (LAB), namely, Lactobacillus rhamnosus (LR5), Lactococ-cuslactis (SL3), Bifidobacterium breve (BR3), and Bifidobacterium lactis (BL3) were evaluated for their anti-C. difficile activity. Co-culture incubation of C. difficile (106 and 1010 CFU/ml) with each strain of LAB indicated that SL3 possessed the highest antimicrobial activity over a 24-hr period. The cell-free supernatants of the 4 LAB strains exhibited MIC50 values between 0.424 mg/ml (SL3) and 1.318 (BR3) mg/ml. These results may provide a basis for alternative therapies for the treatment of C. difficile-associated gut disorders.
